Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omburtamab Lu 177 - Memorial Sloan-Kettering Cancer Center

Next Previous
Drug Profile

Omburtamab Lu 177 - Memorial Sloan-Kettering Cancer Center

Alternative Names: 177Lu-DTPA-omburtamab; 177Lu-omburtamab-DTPA; DPTA-omburtamab; Omburtamab-DPTA; Radiolabeled DPTA-omburtamab

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceuticals
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Medulloblastoma; Meningeal carcinomatosis
  • No development reported Solid tumours

Most Recent Events

  • 31 Dec 2024 Y-mAbs Therapeutics terminates its license for Omburtamab Lu 177 before December 2024
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (Intraventricular)
  • 11 Aug 2022 Y-mAbs Therapeutics terminates phase-I/II trial in Medulloblastoma (In adolescents, In children, Recurrent, Second-line therapy or greater, In adults) in USA, United Kingdom and Denmark (Intraventricular) due to business priorities (NCT04167618) (EudraCT2020-000670-22)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top